We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Decision Making Deficit and DNA Methylation in Opioid Receptor Genes Among Community Heroin Addicts

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01668732
Recruitment Status : Unknown
Verified August 2012 by National Health Research Institutes, Taiwan.
Recruitment status was:  Not yet recruiting
First Posted : August 20, 2012
Last Update Posted : August 20, 2012
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:

Heroin addiction has emerged as a serious problem with tremendous impacts on the addicts and the society. Since the introduction of opioids substitutive treatment in 2006, more than 30,000 heroin addicts had received treatment, and nearly 12,000 continued on treatment currently. However, an unknown proportion of patients hidden in community remained un-treatment. To motivate the community heroin addicts is thus a challenging task.

It is suggested that decision making deficit is core feature which determine outcomes and treatment motivations in patients with addiction disorders. Recently, the state-of-the-art development of epigenetics uncover that environmental modification, via altering level of DNA methylation and gene expression will influence on neurocognitive functioning.

Via respondent-driven sampling, this study aims to recruit a representative sample targeting at the hard-to-reach community heroin addicts. The goal of this study is to identify the clinical feature as well as decision making-related neurocognitive deficit in these patients. Moreover, the investigators will explore the interplay of clinical features, DNA methylation and gene expressions on opioids receptor genes. The findings will help to clarify the clinical characteristics of community heroin addicts, to uncover the links between DNA methylation and clinical features of heroin addiction and to develop modifiable treatment targets in the future.


Condition or disease
Heroin Addiction

Study Design

Study Type : Observational
Estimated Enrollment : 1 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Decision Making Deficit and DNA Methylation in Opioid Receptor Genes Among Community Heroin Addicts
Study Start Date : August 2012
Estimated Primary Completion Date : July 2015
Estimated Study Completion Date : July 2015

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Group/Cohort
community heroin addicts


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
community heroin addicts
Criteria

Inclusion Criteria:

  • 1) 20 to 65 of age; 2) meeting DSM-IV criteria of opioids dependence

Exclusion Criteria:

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01668732


Contacts
Contact: Sheng Chang Wang, M.D., M.Sc. 886-37-246166 ext 36703 scwang69@gmail.com

Sponsors and Collaborators
National Health Research Institutes, Taiwan
Investigators
Principal Investigator: Sheng Chang Wang, M.D., M.Sc. National Health Research Institute, Taiwan
More Information

Responsible Party: National Health Research Institutes, Taiwan
ClinicalTrials.gov Identifier: NCT01668732     History of Changes
Other Study ID Numbers: MD101SCW01
First Posted: August 20, 2012    Key Record Dates
Last Update Posted: August 20, 2012
Last Verified: August 2012

Additional relevant MeSH terms:
Heroin Dependence
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Heroin
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents